
Playing Pfizer’s Q4 Earnings Game: Insights from the Pros Before the Big Release
PFE’s Q4 Top-Line Growth: A Delightful Dance of Non-COVID Drugs and New Acquisitions Let’s embark on an enchanting journey into the world of pharmaceuticals, where numbers dance and deals delight. In the final quarter of 2021, Pfizer Inc. (PFE) reported a remarkable top-line growth, leaving many analysts and investors in awe. PFE’s Non-COVID Drug Portfolio:…